The landscape of acute myeloid leukemia (AML) is shifting faster than at any point in history. Between 2017 and 2024, the FDA approved more new AML drugs than in the previous four decades combined — including targeted therapies for FLT3, IDH1, IDH2, and BCL-2 mutations that are genuinely extending survival for patients who previously had few options. If you’re searching for acute myeloid leukemia latest news and insights, the bottom line is this: AML is no longer a one-size-fits-all disease treated with the same chemotherapy regimen since the 1970s.
That said, AML remains one of the most aggressive blood cancers. The overall 5-year survival rate is still only about 31.7% across all age groups (per SEER data), and outcomes for patients over 65 — who make up the majority of new diagnoses — remain particularly challenging. Here’s what’s actually changing and what it means for patients right now.
What Is AML? A Quick Primer
AML is a cancer of the myeloid lineage — the branch of blood cell development that normally produces red blood cells, platelets, and certain white blood cells (neutrophils, monocytes). In AML, immature cells called myeloblasts accumulate in the bone marrow, crowding out healthy blood production.
Diagnosis requires ≥20% blasts in the bone marrow (or peripheral blood), though certain genetic abnormalities — like t(8;21), inv(16), or PML-RARA fusions — are diagnostic of AML regardless of blast percentage under the updated WHO and ICC classifications released in 2022.
Approximately 20,800 new AML cases are diagnosed annually in the United States, with a median age at diagnosis of 68 years.
The Biggest AML Breakthroughs in Recent Years
Targeted Therapies by Mutation Type
The most transformative shift in AML care is the move toward mutation-driven treatment. Genetic profiling is no longer optional — it’s the standard of care. Here’s a snapshot of the targeted agents now available:
| Mutation/Target | Drug(s) | FDA Approval | Key Benefit |
|---|---|---|---|
| FLT3-ITD/TKD | Midostaurin, gilteritinib, quizartinib | 2017, 2018, 2023 | Quizartinib added to chemo improved median OS by ~3 months in FLT3-ITD+ AML |
| IDH1 | Ivosidenib, olutasidenib | 2018, 2022 | Complete remission rates of 30-40% as monotherapy in relapsed/refractory disease |
| IDH2 | Enasidenib | 2017 | Overall response rate ~40% in relapsed/refractory patients |
| BCL-2 (broad) | Venetoclax + azacitidine | 2018 | Median OS ~14.7 months vs. 9.6 months with azacitidine alone in unfit patients |
| CD33 | Gemtuzumab ozogamicin | Re-approved 2017 | Improved event-free survival in favorable/intermediate-risk AML |
| Hedgehog pathway | Glasdegib + LDAC | 2018 | Median OS 8.8 months vs. 4.9 months with LDAC alone |
Venetoclax: The Game-Changer for Older Patients
Venetoclax combined with azacitidine (ven-aza) has fundamentally reshaped how we treat older or unfit AML patients. Before this regimen, patients who couldn’t tolerate intensive chemotherapy had dismal outcomes — median survival often under 6 months with low-dose options alone.
The VIALE-A trial showed that ven-aza achieved complete remission (CR + CRi) in about 66% of these patients, with a median overall survival of 14.7 months. For patients with IDH1/IDH2 mutations, outcomes were even better, with median OS exceeding 24 months in some subgroups. This combination is now the de facto standard of care for newly diagnosed AML patients who aren’t candidates for intensive “7+3” chemotherapy.
Menin Inhibitors: The Next Frontier
Perhaps the most exciting development in the AML pipeline is the emergence of menin inhibitors like revumenib and ziftomenib, which target KMT2A-rearranged and NPM1-mutated AML — together accounting for roughly 30-40% of all AML cases.
Revumenib received FDA approval in late 2024 for relapsed/refractory KMT2A-rearranged AML after the AUGMENT-101 trial demonstrated a composite complete remission rate of approximately 21% in a heavily pretreated population. Ziftomenib is showing strong efficacy in NPM1-mutated AML in ongoing trials. These agents represent an entirely new mechanism of action, and combination studies with venetoclax and chemotherapy are underway.
AML Risk Stratification: Why Your Mutations Matter More Than Ever
The European LeukemiaNet (ELN) 2022 risk classification divides AML into favorable, intermediate, and adverse-risk categories based primarily on cytogenetics and molecular mutations. This classification directly determines whether a patient is recommended for allogeneic stem cell transplant in first remission.
- Favorable risk: Includes t(8;21), inv(16), NPM1-mutated without FLT3-ITD, bZIP-mutated CEBPA. 5-year OS roughly 60-70%.
- Intermediate risk: Includes NPM1-wild type without adverse features, or NPM1-mutated with FLT3-ITD. 5-year OS roughly 40-50%.
- Adverse risk: Includes TP53 mutations, complex karyotype, monosomal karyotype, RUNX1, ASXL1, or EZH2 mutations. 5-year OS often below 20%.
If you or a family member has been diagnosed with AML, ask the treatment team specifically: “What is my ELN risk category, and does my mutation profile qualify me for any targeted therapies or clinical trials?” This single question can change the trajectory of care.
Recognizing AML Symptoms
AML symptoms develop rapidly — often over days to weeks — because the disease disrupts normal blood cell production. Watch for:
- Fatigue and pallor (from anemia — hemoglobin often drops below 8-9 g/dL)
- Easy bruising, petechiae, or bleeding gums (platelets frequently below 50,000/µL)
- Recurrent or severe infections (functional neutropenia despite potentially high white blood cell counts)
- Bone pain (from marrow expansion)
- Gum hypertrophy or skin nodules (more common in monocytic subtypes like M4/M5)
A CBC showing unexplained blasts in the peripheral blood — even a few percent — warrants urgent hematology referral. Don’t wait.
When to See a Doctor
Seek immediate medical evaluation if you develop unexplained fatigue combined with bruising, bleeding, or recurrent fevers. AML can progress from first symptom to life-threatening complication within days. A simple CBC is the first step, and if it shows blasts or a markedly abnormal differential, you’ll need a bone marrow biopsy urgently — ideally within 24-48 hours.
For patients already diagnosed, seek a second opinion at an academic center or NCI-designated cancer center if you haven’t already. Access to clinical trials and specialized molecular testing can meaningfully change outcomes.
Frequently Asked Questions
What is the survival rate for AML in 2024?
The overall 5-year survival for AML is approximately 31.7%, but this varies enormously by age and risk category. Patients under 60 with favorable-risk genetics have 5-year survival rates approaching 65-70%, while patients over 75 with adverse-risk features may have median survival under 6-12 months even with treatment. New therapies like venetoclax combinations and menin inhibitors are improving these numbers, particularly for specific mutation subtypes.
Is AML curable?
Yes — for some patients. Roughly 35-40% of younger adults (under 60) with AML are cured with intensive chemotherapy, with or without allogeneic stem cell transplant. Favorable-risk AML (e.g., core binding factor leukemias) has cure rates exceeding 60%. For older patients, cure is less common, but durable remissions lasting years are increasingly achievable with newer regimens.
What is the most promising new AML treatment?
Menin inhibitors (revumenib, ziftomenib) are generating the most excitement because they target two of the most common AML driver mutations — KMT2A rearrangements and NPM1 mutations. Combination trials pairing menin inhibitors with venetoclax and/or chemotherapy are expected to report results in 2025 and could represent a major advance for a large percentage of AML patients.
Does AML run in families?
Sporadic AML — the vast majority of cases — is not inherited. However, rare germline mutations in genes like CEBPA, RUNX1, DDX41, GATA2, and ANKRD26 cause hereditary predisposition to myeloid malignancies. The 2022 WHO classification now formally recognizes “myeloid neoplasms with germline predisposition” as a distinct category. If multiple family members have had blood cancers or bone marrow failure, genetic counseling is worth pursuing.
Can you get AML from chemotherapy for another cancer?
Yes. Therapy-related AML (t-AML) accounts for roughly 10-20% of all AML cases and can develop years after exposure to alkylating agents (e.g., cyclophosphamide) or topoisomerase II inhibitors (e.g., etoposide). t-AML tends to carry adverse-risk cytogenetics and historically has had poor outcomes, though newer targeted agents are offering some improvement depending on the mutation profile.
